Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation.

Trial Profile

Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Rituximab (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Methotrexate
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms HOVON 80 NHL
  • Most Recent Events

    • 30 Jan 2014 Status changed from recruiting to active, no longer recruiting as per Hovon.nl (www.Hovon.nl) record
    • 14 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top